Business Context and Reporting Period
This Form 8-K Current Report from Harvard Bioscience, Inc. covers events occurring on June 2, 2026, specifically the results of the Company's 2026 Annual Meeting of Stockholders. The filing details the approval of corporate governance proposals, including director elections, auditor ratification, executive compensation, and amendments to equity incentive plans.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only quantitative financial-related data provided pertains to equity plan share availability:
- 2021 Incentive Plan Shares Available (as of Dec 31, 2025): 646,520 shares.
- Incentive Plan Share Increase: 400,000 additional shares authorized following stockholder approval.
Material Changes Versus Prior Period
The filing reports the following material changes resulting from the June 2, 2026, Annual Meeting:
- Equity Plan Expansion: The Amended and Restated 2021 Incentive Plan was approved, increasing the pool of shares available for issuance by 400,000.
- ESPP Amendment: The Employee Stock Purchase Plan (ESPP) was amended to increase the number of authorized shares available for issuance.
- Board Composition: Two Class II Directors, John Duke and Katherine A. Eade, were elected to three-year terms ending in 2029.
- Auditor Ratification: Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Guidance, Outlook, and Voting Results
The filing does not provide forward-looking guidance, management commentary on future operations, or risk factors. It focuses on the voting outcomes of five proposals:
- Proposal 1 (Directors): John Duke received 1,800,288 votes for; Katherine A. Eade received 1,680,982 votes for.
- Proposal 2 (Auditor): Ratified with 2,781,705 votes for and 13,975 against.
- Proposal 3 (Executive Compensation): Approved with 1,768,695 votes for and 57,111 against.
- Proposal 4 (ESPP Amendment): Approved with 1,705,565 votes for and 90,905 against.
- Proposal 5 (Incentive Plan Amendment): Approved with 1,131,261 votes for and 680,030 against. This proposal received the highest number of "Against" votes among the five proposals.
Investor Verification Checklist
- Verify the total number of shares outstanding to assess the dilution impact of the 400,000 new shares added to the Incentive Plan.
- Review the Definitive Proxy Statement (filed April 21, 2026) for the full text of the Amended and Restated 2021 Incentive Plan and the ESPP amendment.
- Monitor the high number of "Against" votes (680,030) on Proposal 5 regarding the Incentive Plan amendment, which may indicate shareholder sentiment regarding equity dilution.
- Confirm the terms of the newly elected directors' three-year tenure ending in 2029.